Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services
Evotec AG and DiscoveRx Corporation announced a co-marketing agreement for the screening of GPCR’s and other targets. Under the terms of the agreement, Evotec will have access to DiscoveRx’s PathHunter™ and cAMPHunter™ cell lines and proprietary EFC chemiluminescent detection technology for use during hit identification and optimization projects performed for Evotec customers, using the Company’s proprietary high throughput screening platform.
Evotec’s Executive Vice President, Business Development, Dr Mark Ashton commented: “We are constantly seeking opportunities to further enhance our Discovery Alliance Business (DAB). For our customers, this agreement means that DiscoveRx’s innovative assay portfolio of more than 300 cell based GPCR assays can be accessed in conjunction with the first-class high throughput screening set-up at Evotec. This will provide significant value to our screening partners, specifically in the area of GPCR screening.”
Other news from the department business & finance
